Nov 02, 2021 7:00am EDT Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Oct 26, 2021 8:00am EDT Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021
Oct 06, 2021 8:00am EDT Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer
Aug 24, 2021 9:00am EDT Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor
Aug 04, 2021 7:00am EDT Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Jul 28, 2021 8:00am EDT Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021
Jun 25, 2021 7:00am EDT Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis
Jun 24, 2021 8:00am EDT Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer
